Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...

“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OCREVUS IV 600 ...

Dicerna Pharma has enticed another big pharma to partner its RNA interference platform, attracting a $200 million upfront deal with Roche for a drug to treat hepatitis B virus infections.

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...

A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

The Delhi High Court on Monday dismissed an interim injunction application filed by Swiss pharmaceutical giant F Hoffmann-La ...

Patients with Spinal Muscular Atrophy (SMA) are hopeful of getting access to generic versions of Roche’s patented drug ...

For some Big Pharma companies, sales in China contributed to more than 10 percent of global sales, making China a top market ...

A Weld District judge denied a motion Wednesday that would force Trevor George — suspected of killing another man and ...